Cambridge Cognition and Ivory to Roll Out Digital Cognitive Screening Across India

The latest update is out from Cambridge Cognition Holdings ( (GB:COG) ).

Cambridge Cognition has entered a strategic partnership with Indian brain health startup Ivory to commercialise its CANTAB Pathway digital cognitive assessment platform across professional healthcare and consumer health markets in India. Leveraging Ivory’s expanding clinical network, consumer app and health-tech partnerships, the deal aims to scale early cognitive screening in a country where tens of millions of older adults may have undiagnosed impairment and where demand for proactive, tech-enabled brain health tools is rising.

The collaboration will see CANTAB Pathway deployed at scale, offering validated, low-burden tests with real-time results in multiple Indian languages, with further localisation planned. By combining Cambridge Cognition’s scientifically validated assessments with Ivory’s mission to shift care from late-stage diagnosis to prevention, the agreement positions both companies to tap India’s growing middle and affluent classes and address a substantial unmet need in early detection of neurodegenerative conditions, potentially improving outcomes for patients and strengthening their presence in the global brain health market.

The most recent analyst rating on (GB:COG) stock is a Hold with a £36.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.

Spark’s Take on GB:COG Stock

According to Spark, TipRanks’ AI Analyst, GB:COG is a Neutral.

Overall score reflects weak financial performance driven by declining revenue, ongoing losses, and negative operating/free cash flow, partially offset by improved equity on the balance sheet. Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while valuation is constrained by loss-making results and no stated dividend yield.

To see Spark’s full report on GB:COG stock, click here.

More about Cambridge Cognition Holdings

Cambridge Cognition Holdings is a neuroscience technology company that develops digital cognitive assessments under the CANTAB and Winterlight brands to support scientific discovery, accelerate drug development and improve patient care. Its touchscreen and voice-based tools, including the scalable CANTAB Pathway suite, are designed for minimal specialist administration, real-time objective results, and longitudinal monitoring in both clinical and consumer settings, with wide multilingual support.

Average Trading Volume: 26,876

Technical Sentiment Signal: Hold

Current Market Cap: £18.39M

Find detailed analytics on COG stock on TipRanks’ Stock Analysis page.